Sona Nanotech Ltd. specializes in the development of biocompatible gold nanoparticles, particularly gold nanorods (GNRs) and gold nanospheres, which are being utilized in innovative cancer therapies and rapid diagnostic applications. The company's GNR technology is designed to enable targeted hyperthermia therapy (THT), a method that aims to treat cancer by applying therapeutic heat to solid tumors while minimizing damage to surrounding healthy tissues. This approach is being explored in preclinical studies, particularly in collaboration with the Giacomantonio Immuno-Oncology Research Group, to evaluate its effectiveness in enhancing immune responses against various cancers, including colorectal, skin, and breast cancers.

In addition to therapeutic applications, Sona's gold nanoparticles are also being developed for diagnostic purposes, such as concussion screening tests and early detection of bovine tuberculosis. The unique properties of these nanoparticles, including their optical and electronic characteristics, make them suitable for advanced medical diagnostics and lateral flow assays. Sona Nanotech's commitment to leveraging nanotechnology in both therapeutic and diagnostic fields positions it at the forefront of innovative solutions in cancer treatment and disease detection.

Canada

Purdy's Wharf Tower II Suite 2001, 1969 Upper Water Street

Sona Nanotech Ltd.

Sona Nanotech Ltd.

Company Details